Visual Quality and Performance of Eyes With Asqelio™ EDoF Toric Lenses

NCT ID: NCT06707545

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-11

Study Completion Date

2024-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the optical quality and clinical performance of the Asqelio™ EDOF Toric intraocular lens (IOL) in patients undergoing cataract surgery or refractive lensectomy. The Asqelio™ EDOF Toric IOL aims to provide improved vision at various distances and correct astigmatism compared to monofocal IOLs. Postoperative outcomes, including visual clarity, refractive correction, and patient satisfaction, will be assessed three months after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cataract surgery is one of the most common procedures worldwide, typically involving the replacement of the cloudy natural lens with an intraocular lens (IOL). Traditional monofocal IOLs correct vision for a single distance but do not address intermediate or near vision, leading to dependence on glasses. The Asqelio™ EDOF Toric IOL is designed to provide extended depth of focus, smoother transitions across distances, and astigmatism correction, potentially enhancing overall visual quality and reducing the need for glasses.

This study compares the optical performance and patient outcomes of the Asqelio™ EDOF Toric IOL with those of monofocal IOLs. Key measures include optical quality, visual acuity at multiple distances, refractive correction, and patient-reported satisfaction. Results will be collected during a three-month postoperative follow-up. The findings aim to inform the effectiveness of the Asqelio™ EDOF Toric IOL in improving visual outcomes and quality of life for patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Presbyopia Correction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asqelio EDOF

Patients submitted to cataract surgery and implanted with the extended depth-of-focus intraocular lens Asqelio EDOF Toric

No interventions assigned to this group

Monofocal IOL

Patients submitted to cataract surgery and implanted with the TECNIS 1-Piece monofocal intraocular lens

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 50 years or older who have undergone cataract surgery with phacoemulsification or refractive lensectomy, with bilateral implantation of the Asqelio EDOF toric IOL model ETLIO130C/ETPIO130C with a cylinder value of 0.0 D, or the spherical monofocal J\&J TECNIS 1-Piece IOL model ZCB00.
* Patients who have signed the informed consent form.
* Clear intraocular media, except for the presence of cataracts in both eyes prior to surgery.
* Postoperative potential visual acuity of 20/25 or better

Exclusion Criteria

* Preoperative corneal astigmatism greater than 1.00D.
* Patients who do not provide informed consent.
* Patients who do not understand the study procedure.
* Previous corneal surgery or trauma.
* Irregular cornea (e.g., keratoconus).
* Choroidal hemorrhage.
* Microphthalmos.
* Severe corneal dystrophy.
* Uncontrolled or medically controlled glaucoma.
* Clinically significant macular changes.
* Severe concomitant ocular disease.
* Cataract unrelated to aging.
* Severe optic nerve atrophy.
* Diabetic retinopathy.
* Proliferative diabetic retinopathy.
* Amblyopia.
* Extremely shallow anterior chamber.
* Severe chronic uveitis.
* Pregnant or breastfeeding.
* Rubella.
* Mature/dense cataract preventing preoperative fundus examination.
* Previous retinal detachment.
* Concurrent participation in another drug or clinical device investigation.
* Expectation of needing another ocular surgery during the study period
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AST Products, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Cano, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital La Arruzafa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital La Arruzafa

Córdoba, Cordoba, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASQE022022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ICL and LASIK for Hyperopic Astigmatism
NCT06742541 COMPLETED EARLY_PHASE1